同種T細胞治療の世界市場レポート 2025年

同種T細胞治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で18億5,000万米ドルに成長します。予測期間の成長は、適応症の拡大、細胞ベースの免疫療法に対する需要の高まり、先進治療に対する意識の高まり、ヘルスケア支出の増加、償還政策の支援などに起因すると考えられます。予測期間の世界の動向には、研究開発活動の進展、個別化医療、既製療法、世界市場の拡大、戦略的提携、規制状況の進化などが含まれます。

がん罹患率の増加が同種T細胞治療市場の拡大を牽引すると予想されます。がんは、体内の異常細胞の無秩序な増殖と拡散によって特徴づけられる疾患群です。がん患者の増加は、平均寿命の伸び、ライフスタイルの変化、環境暴露、感染症、遺伝的素因、生殖パターンの変化などの要因に関連しており、これらすべてががんの発生率や発見率の上昇に寄与しています。同種T細胞治療では、遺伝子操作されたドナーのT細胞を注入し、がん細胞を標的として破壊する方法が、がん治療に用いられるようになってきています。2024年5月の米国国立がん研究所によると、米国におけるがん生存者数は約1,810万人で、2032年には2,250万人に増加すると予測されています。2040年には、年間新規がん患者数は2,990万人に達し、がん関連死は1,530万人に増加すると予想されています。これらの動向は、同種T細胞治療市場の成長を促進すると予想されます。

同種T細胞治療市場の主要企業は、治療効果の向上と治療選択肢の拡大を目指し、革新的なキメラ抗原受容体（CAR）T細胞療法プログラムの開発に注力しています。こうした先進的な取り組みは、がんに対するCAR T細胞療法の効率性、アクセシビリティ、デリバリーの向上を目指しています。例えば、米国を拠点とするバイオテクノロジー企業Allogene Therapeutics Inc.は、2022年10月、CAR T療法のデリバリーとアクセシビリティに関する課題に対処することを目的としたイニシアチブ、CAR T Togetherを開始しました。このプログラムは、同種CAR T療法の開発を促進するために、臨床試験登録を合理化し、腫瘍内科医間の協力を促進することを目的としています。患者自身の細胞を使用する自家療法とは異なり、同種療法は健康なドナーからのT細胞に依存するため、より効率的な製造工程が可能となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界同種T細胞治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の同種T細胞治療市場：成長率分析
• 世界の同種T細胞治療市場の実績：規模と成長, 2019-2024
• 世界の同種T細胞治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界同種T細胞治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の同種T細胞治療市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• キメラ抗原受容体（CAR）T細胞療法
• T細胞受容体（TCR）療法
• その他の製品タイプ
• 世界の同種T細胞治療市場抗原の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• CD 19
• CD 20
• エグフリブル
• GD2
• CD22
• CD30
• CD33
• メソ
• HER1
• その他の抗原タイプ
• 世界の同種T細胞治療市場治療適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 自己免疫疾患
• 感染症
• その他の治療薬の適応症
• 世界の同種T細胞治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 調査機関
• その他のエンドユーザー
• 世界の同種T細胞治療市場キメラ抗原受容体（CAR）T細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• CD19標的CAR-T療法
• BCMA標的CAR-T療法
• CD22標的CAR-T療法
• 世界の同種T細胞治療市場T細胞受容体（TCR）療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ネオアンチゲン標的TCR療法
• ウイルス抗原標的TCR療法
• 世界の同種T細胞治療市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子組み換えT細胞療法
• NK細胞療法

第7章 地域別・国別分析

• 世界の同種T細胞治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の同種T細胞治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 同種T細胞治療市場：競合情勢
• 同種T細胞治療市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Immatics NV Overview, Products and Services, Strategy and Financial Analysis
  • Sangamo Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Poseida Therapeutics Inc.
• Fate Therapeutics Inc.
• Atara Biotherapeutics Inc.
• Sorrento Therapeutics Inc
• Autolus Therapeutics Plc
• MaxCyte Inc.
• Tessa Therapeutics Pte Ltd.
• Cell Medica Inc.
• Enlivex Therapeutics Ltd.
• Cellectis SA
• Adaptimmune Therapeutics Plc
• Medigene AG
• Celyad Oncology SA
• Allogene Therapeutics Inc
• Bellicum Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 同種T細胞治療市場2029：新たな機会を提供する国
• 同種T細胞治療市場2029：新たな機会を提供するセグメント
• 同種T細胞治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Allogeneic T cell therapies represent an advanced medical approach where T cells, critical to the immune system, are sourced from a donor and utilized to attack cancer cells in a recipient. These therapies are primarily applied in the treatment of challenging cancers that are resistant to conventional therapies.

The key forms of allogeneic T cell therapies include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. CAR T-cell therapies are a type of immunotherapy where T-cells are genetically engineered to target and eliminate cancer cells by recognizing specific proteins on them. Targeted antigens in these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, among others. These therapies address various conditions such as cancer, autoimmune disorders, and infectious diseases, with applications spanning hospitals, specialty clinics, research institutions, and other healthcare facilities.

The allogeneic T cell therapies market research report is one of a series of new reports from The Business Research Company that provides allogeneic T cell therapies market statistics, including the allogeneic T cell therapies industry's global market size, regional shares, competitors with an allogeneic T cell therapies market share, detailed allogeneic T cell therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the allogeneic T cell therapies industry. This allogeneic T cell therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The allogeneic t cell therapies market size has grown rapidly in recent years. It will grow from $1.16 billion in 2024 to $1.28 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to regulatory approvals, increasing cancer prevalence, rising clinical trials, government funding, and a growing geriatric population.

The allogeneic t cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding indications, rising demand for cell-based immunotherapies, growing awareness about advanced therapies, increasing healthcare expenditure, and supportive reimbursement policies. Major trends in the forecast period include advancement in research and development activities, personalized medicine, off-the-shelf therapies, global market expansion, strategic partnerships, and regulatory landscape evolution.

The growing incidence of cancer is expected to drive the expansion of the allogeneic T cell therapies market. Cancer is a group of diseases marked by the uncontrolled proliferation and spread of abnormal cells in the body. The rise in cancer cases is linked to factors such as increased life expectancy, lifestyle changes, environmental exposures, infections, genetic predispositions, and shifts in reproductive patterns, all of which contribute to a higher incidence and detection of cancer. Allogeneic T cell therapies, which involve infusing genetically engineered donor T cells to target and destroy cancer cells, are increasingly being used in cancer treatment. According to the National Cancer Institute in May 2024, there were approximately 18.1 million cancer survivors in the U.S., a number projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths rising to 15.3 million. These trends are expected to propel the growth of the allogeneic T cell therapies market.

Leading companies in the allogeneic T cell therapies market are focusing on developing innovative chimeric antigen receptor (CAR) T-cell therapy programs to enhance treatment effectiveness and broaden therapeutic options. These advanced initiatives aim to improve the efficiency, accessibility, and delivery of CAR T-cell therapies for cancer. For example, in October 2022, Allogene Therapeutics Inc., a U.S.-based biotechnology company, launched CAR T Together, an initiative aimed at addressing challenges related to the delivery and accessibility of CAR T therapies. The program seeks to streamline clinical trial enrollment and foster collaboration among oncologists to expedite the development of allogeneic CAR T therapies. Unlike autologous therapies, which use a patient's own cells, allogeneic therapies rely on T cells from healthy donors, allowing for more efficient manufacturing processes.

In January 2023, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed sum. This acquisition is part of AstraZeneca's strategy to advance innovative treatments and bolster its oncology capabilities, particularly in developing therapies for solid tumors that target cancer-specific mutations. Neogene Therapeutics Inc. is a U.S.-based biotechnology firm specializing in allogeneic T cell therapies.

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc, Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc, Bellicum Pharmaceuticals Inc.

North America was the largest region in the allogeneic T cell therapies market in 2023. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allogeneic t cell therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allogeneic T Cell Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allogeneic t cell therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allogeneic t cell therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The allogeneic t cell therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies; T Cell Receptor (TCR) Therapies; Other Product Types
• 2) By Antigen Type: CD 19; CD 20; Egfrvlll; GD2; CD22; CD30; CD33; Meso; HER1; Other Antigen Types
• 3) By Therapeutics Indications: Cancer; Autoimmune Diseases; Infectious Diseases; Others Therapeutics Indications
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
• Subsegments:
• 1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies; BCMA-targeted CAR T Therapies; CD22-targeted CAR T Therapies
• 2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies; Viral Antigen-targeted TCR Therapies
• 3) By Other Product Types: Engineered T Cell Therapies; NK Cell Therapies
• Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences Inc.; Immatics NV; Sangamo Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Allogeneic T Cell Therapies Market Characteristics

3. Allogeneic T Cell Therapies Market Trends And Strategies

4. Allogeneic T Cell Therapies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Allogeneic T Cell Therapies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Allogeneic T Cell Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Allogeneic T Cell Therapies Market Growth Rate Analysis
• 5.4. Global Allogeneic T Cell Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Allogeneic T Cell Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Allogeneic T Cell Therapies Total Addressable Market (TAM)

6. Allogeneic T Cell Therapies Market Segmentation

• 6.1. Global Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Antigen Receptor (CAR) T Cell Therapies
• T Cell Receptor (TCR) Therapies
• Other Product Types
• 6.2. Global Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CD 19
• CD 20
• Egfrvlll
• GD2
• CD22
• CD30
• CD33
• Meso
• HER1
• Other Antigen Types
• 6.3. Global Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others Therapeutics Indications
• 6.4. Global Allogeneic T Cell Therapies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Other End-Users
• 6.5. Global Allogeneic T Cell Therapies Market, Sub-Segmentation Of Chimeric Antigen Receptor (CAR) T Cell Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CD19-targeted CAR T Therapies
• BCMA-targeted CAR T Therapies
• CD22-targeted CAR T Therapies
• 6.6. Global Allogeneic T Cell Therapies Market, Sub-Segmentation Of T Cell Receptor (TCR) Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neoantigen-targeted TCR Therapies
• Viral Antigen-targeted TCR Therapies
• 6.7. Global Allogeneic T Cell Therapies Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Engineered T Cell Therapies
• NK Cell Therapies

7. Allogeneic T Cell Therapies Market Regional And Country Analysis

• 7.1. Global Allogeneic T Cell Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Allogeneic T Cell Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Allogeneic T Cell Therapies Market

• 8.1. Asia-Pacific Allogeneic T Cell Therapies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Allogeneic T Cell Therapies Market

• 9.1. China Allogeneic T Cell Therapies Market Overview
• 9.2. China Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Allogeneic T Cell Therapies Market

• 10.1. India Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Allogeneic T Cell Therapies Market

• 11.1. Japan Allogeneic T Cell Therapies Market Overview
• 11.2. Japan Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Allogeneic T Cell Therapies Market

• 12.1. Australia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Allogeneic T Cell Therapies Market

• 13.1. Indonesia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Allogeneic T Cell Therapies Market

• 14.1. South Korea Allogeneic T Cell Therapies Market Overview
• 14.2. South Korea Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Allogeneic T Cell Therapies Market

• 15.1. Western Europe Allogeneic T Cell Therapies Market Overview
• 15.2. Western Europe Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Allogeneic T Cell Therapies Market

• 16.1. UK Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Allogeneic T Cell Therapies Market

• 17.1. Germany Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Allogeneic T Cell Therapies Market

• 18.1. France Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Allogeneic T Cell Therapies Market

• 19.1. Italy Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Allogeneic T Cell Therapies Market

• 20.1. Spain Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Allogeneic T Cell Therapies Market

• 21.1. Eastern Europe Allogeneic T Cell Therapies Market Overview
• 21.2. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Allogeneic T Cell Therapies Market

• 22.1. Russia Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Allogeneic T Cell Therapies Market

• 23.1. North America Allogeneic T Cell Therapies Market Overview
• 23.2. North America Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Allogeneic T Cell Therapies Market

• 24.1. USA Allogeneic T Cell Therapies Market Overview
• 24.2. USA Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Allogeneic T Cell Therapies Market

• 25.1. Canada Allogeneic T Cell Therapies Market Overview
• 25.2. Canada Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Allogeneic T Cell Therapies Market

• 26.1. South America Allogeneic T Cell Therapies Market Overview
• 26.2. South America Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Allogeneic T Cell Therapies Market

• 27.1. Brazil Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Allogeneic T Cell Therapies Market

• 28.1. Middle East Allogeneic T Cell Therapies Market Overview
• 28.2. Middle East Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Allogeneic T Cell Therapies Market

• 29.1. Africa Allogeneic T Cell Therapies Market Overview
• 29.2. Africa Allogeneic T Cell Therapies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Allogeneic T Cell Therapies Market, Segmentation By Antigen Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Allogeneic T Cell Therapies Market, Segmentation By Therapeutics Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Allogeneic T Cell Therapies Market Competitive Landscape And Company Profiles

• 30.1. Allogeneic T Cell Therapies Market Competitive Landscape
• 30.2. Allogeneic T Cell Therapies Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Immatics NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sangamo Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Allogeneic T Cell Therapies Market Other Major And Innovative Companies

• 31.1. Poseida Therapeutics Inc.
• 31.2. Fate Therapeutics Inc.
• 31.3. Atara Biotherapeutics Inc.
• 31.4. Sorrento Therapeutics Inc
• 31.5. Autolus Therapeutics Plc
• 31.6. MaxCyte Inc.
• 31.7. Tessa Therapeutics Pte Ltd.
• 31.8. Cell Medica Inc.
• 31.9. Enlivex Therapeutics Ltd.
• 31.10. Cellectis SA
• 31.11. Adaptimmune Therapeutics Plc
• 31.12. Medigene AG
• 31.13. Celyad Oncology SA
• 31.14. Allogene Therapeutics Inc
• 31.15. Bellicum Pharmaceuticals Inc.

32. Global Allogeneic T Cell Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Allogeneic T Cell Therapies Market

34. Recent Developments In The Allogeneic T Cell Therapies Market

35. Allogeneic T Cell Therapies Market High Potential Countries, Segments and Strategies

• 35.1 Allogeneic T Cell Therapies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Allogeneic T Cell Therapies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Allogeneic T Cell Therapies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer